Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer.

Endocrine

Medical Faculty, Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06097, Halle (Saale), Germany.

Published: September 2024

AI Article Synopsis

  • The study looked at patients with medullary thyroid cancer (MTC) who had surgery over a 30-year period to see how often it happens in young people.
  • Out of 1252 patients, only 4 who were under 18 years old had sporadic MTC, which means it wasn't passed down from their parents.
  • These young patients had much larger tumors compared to those with hereditary MTC, suggesting sporadic MTC is rare in kids and teens.

Article Abstract

Purpose: No genomic data have been put forth that prove beyond a shadow of doubt that sporadic medullary thyroid cancer (MTC) occurs in infancy, childhood, and/or adolescence.

Methods: This was a retrospective comparative study of consecutive patients with MTC who had neck surgery at a tertiary center over a 30-year period.

Results: Included were 1252 patients with MTC (337 hereditary and 915 sporadic), of whom 107 (8.5%) were operated before the age of 18 yrs. Only 4 (3.7%) of the 107 pediatric patients, aged 14, 16, 17 and 17 years, had sporadic MTC. These 4 patients, 3 of whom had been referred for completion surgery, revealed much larger thyroid tumors (medians of 20 mm vs. 1.5-5 mm) than the 103 pediatric patients with hereditary MTC. As for extrathyroid extension and nodal metastases, the 4 patients with sporadic MTC were more comparable to the 37 carriers of highest-risk mutations, 31 (84%) of whom were index patients with de novo disease, than to the 66 carriers of high-risk, intermediate-risk, or low-risk RET mutations (25-38% vs. 0-8%, and medians of 9-9.5 vs. 0 node metastases after dissection of more (medians of 72-91.5 vs. 4.5-9) nodes).

Conclusion: Sporadic MTC, arising rarely, if ever, below the age of 14 years, is exceptional in infancy and childhood, and infrequent in adolescence. At diagnosis, it is almost as widely metastatic as hereditary MTC of the highest-risk category which almost always, like sporadic MTC, presents as de novo disease.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-024-03959-1DOI Listing

Publication Analysis

Top Keywords

sporadic mtc
16
mtc
9
medullary thyroid
8
thyroid cancer
8
infancy childhood
8
patients mtc
8
pediatric patients
8
hereditary mtc
8
novo disease
8
sporadic
7

Similar Publications

Dissection of RET p.M918T-driven progression of hereditary vs. sporadic medullary thyroid cancer.

Eur J Surg Oncol

December 2024

Medical Faculty, Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06097, Halle (Saale), Germany; Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen, D-45122, Essen, Germany.

Background: Whether inherited in the context of multiple endocrine neoplasia 2B at germline level or acquired in a lifetime, all RET p.M918T (RET c.2753T>C) mutations should activate the RET tyrosine kinase receptor alike, with similar degrees of medullary thyroid cancer (MTC) progression when disparities in disease onset and multifocal growth are accounted for.

View Article and Find Full Text PDF

Two selective RET inhibitors (RETis) are effective in treating ()-altered medullary thyroid carcinoma (MTC), but clinical trials did not distinguish responses between hereditary MTC (hMTC) and sporadic MTC (sMTC) cases. We reviewed our single-center experience using a RETi to treat advanced hMTC. We conducted a retrospective cohort study of patients with hMTC treated with a selective RETi at a tertiary cancer center.

View Article and Find Full Text PDF

The Potential Utility of RAS Q61R Immunohistochemistry as a Screening Tool in Pre-operative Fine Needle Aspirates of Medullary Thyroid Carcinoma.

Endocr Pathol

December 2024

Department of Pathology and Laboratory Medicine, Emory University Hospital Midtown, 550 Peachtree St NE, Suite 1323, Davis-Fisher Building, Atlanta, GA, 30309, USA.

Medullary thyroid carcinoma (MTC) can either be sporadic, often via mutually exclusive RET or RAS alterations, or inherited via a RET germline alteration. Germline testing is recommended for all patients diagnosed with MTC. RAS p.

View Article and Find Full Text PDF
Article Synopsis
  • - Medullary thyroid carcinoma (MTC) is a rare cancer linked to mutations in the RET proto-oncogene, with specific treatments available for cases involving these mutations.
  • - Selective RET inhibitors have been approved for clinical use, showing effectiveness with low toxicity, but treatment options are limited for patients with RET-negative MTC.
  • - Peptide receptor radionuclide therapy (PRRT) is being explored as a potential option for treatment, although its effectiveness compared to current therapies is still being studied.
View Article and Find Full Text PDF

Cushing disease (CD), a rare endocrine disorder characterized by a pituitary adenoma that secretes excess adrenocorticotropic hormone (ACTH), leads to overproduction of cortisol by the adrenal glands and, depending on severity and duration, manifests with a broad spectrum of clinical signs and symptoms, ranging from classical features to more common conditions seen in the general population. Discovery of molecular and pathogenic mechanisms related to the development of CD tumors has increased in recent years, almost two-thirds of the somatic variants cases have been linked to the USP8 gene, while very rare germline variants in MEN1 and AIP genes have been associated with pituitary adenomas. Variants affecting the RET proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth and differentiation, are implicated in the development of medullary thyroid carcinoma (MTC) and its hereditary form, multiple endocrine neoplasia type 2 (MEN2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!